دورية أكاديمية
Health Care Resource Utilization and Costs Associated with Disease Progression in Ovarian Cancer.
| العنوان: | Health Care Resource Utilization and Costs Associated with Disease Progression in Ovarian Cancer. |
|---|---|
| المؤلفون: | Simmons D; US Oncology Health Economics and Outcomes Research, AstraZeneca, 1 Medimmune Way, Gaithersburg, MD, 20878, USA. daniel.simmons@astrazeneca.com., Blank SV; Icahn School of Medicine at Mount Sinai, Blavatnik Family Women's Health Research Institute, New York, NY, USA., ElNaggar AC; WEST Cancer Center and Research Institute, Memphis, TN, USA., Chastek B; Optum, Eden Prairie, MN, USA., Bunner SH; Optum, Eden Prairie, MN, USA., McLaurin K; US Oncology Health Economics and Outcomes Research, AstraZeneca, 1 Medimmune Way, Gaithersburg, MD, 20878, USA. |
| المصدر: | Advances in therapy [Adv Ther] 2022 Jun; Vol. 39 (6), pp. 2544-2561. Date of Electronic Publication: 2022 Apr 01. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-8652 (Electronic) Linking ISSN: 0741238X NLM ISO Abbreviation: Adv Ther |
| أسماء مطبوعة: | Publication: New York : Springer Healthcare Communications, 2008- : Health Communications Inc. Original Publication: Metuchen, N.J. : Health Communications Inc., c1984- |
| مواضيع طبية MeSH: | Medicare* , Ovarian Neoplasms*/drug therapy, Aged ; Carcinoma, Ovarian Epithelial/therapy ; Delivery of Health Care ; Disease Progression ; Female ; Health Care Costs ; Humans ; Retrospective Studies ; United States |
| مستخلص: | Introduction: Ovarian cancer (OC) is one of the leading causes of cancer mortality among women in the United States. With the approval of first-line maintenance therapies, patients with OC experienced prolonged first-line progression-free survival. While the literature addresses some costs associated with OC, further research is needed on the costs of progression that are potentially deferred or prevented by early maintenance. The objective of this study was to capture the health care resource utilization and costs of patients with advanced OC who never received poly(ADP ribose) polymerase (PARP) inhibitor maintenance. Methods: We conducted a descriptive retrospective analysis of treatment patterns and the consequences of progression through several lines of therapy (LOTs) in patients with OC, using claims from commercial and Medicare Advantage health plan members in the United States from the Optum Research Database between January 1, 2010, and April 30, 2019. Patients were required to have an index OC diagnosis (≥ 2 non-diagnostic claims). We examined up to 4 LOTs and the time between treatments. Results: A total of 5498 women met the eligibility criteria. As the number of LOTs increased, the median duration of each line decreased from 137 days in LOT1 to 94 days in LOT4, and the time between lines also decreased from 245 to 0 days. Ambulatory care visits were a major driver of health care resource utilization, with a median of about 6 monthly visits during active treatment. The mean total monthly health care costs for patients with at least 2 LOTs were US$8588 (SD: $8533) before LOT2 and increased to $15,358 (SD: $21,460) during or after LOT2. Conclusions: Prolonging progression-free survival after first-line treatment in patients with OC may provide the opportunity to delay or prevent later treatment, the financial toxicity felt by patients, and the economic burden to the health care system associated with progression. (© 2022. The Author(s).) |
| References: | West K, Borley J. Ovarian, fallopian tube and primary peritoneal cancer: an overview. Obstet Gynaecol Reprod Med. 2020;30(12):380–6. (PMID: 10.1016/j.ogrm.2020.10.001) Kim J, Park EY, Kim O, et al. Cell origins of high-grade serous ovarian cancer. Cancers. 2018;10:433. (PMID: 10.3390/cancers10110433) Cancer Stat Facts: Ovarian Cancer. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. https://seer.cancer.gov/statfacts/html/ovary.html . Accessed 13 May 2021. Doubeni CA, Doubeni ARB, Myers AE. Diagnosis and management of ovarian cancer. Am Fam Phys. 2016;93(11):937–44. American Cancer Society. Cancer Facts & Figures 2018. Special Section: Ovarian Cancer. Atlanta: American Cancer Society; 2018. Sato S, Itamochi H. Neoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapy. Ther Adv Med Oncol. 2014;6(6):293–304. (PMID: 10.1177/1758834014544891) Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69:280–304. (PMID: 31099893) Dockery LE, Rubenstein AR, Ding K, et al. Extending the platinum-free interval: the impact of omitting 2nd line platinum chemotherapy in intermediate platinum-sensitive ovarian cancer. Gynecol Oncol. 2019;155(2):201–6. (PMID: 10.1016/j.ygyno.2019.07.008) Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 1998;16(2):405–10. (PMID: 10.1200/JCO.1998.16.2.405) Balbi G, Di Prisco L, Musone R, et al. Second-line with paclitaxel and carboplatin for recurrent disease following first paclitaxel and platinum compounds in ovarian carcinoma. Eur J Gynaecol Oncol. 2002;23(4):347–9. (PMID: 12214742) Hoekstra AV, Hurteau JA, Kirschner CV, Rodriguez GC. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer. Gynecol Oncol. 2009;115(3):377–81. (PMID: 10.1016/j.ygyno.2009.08.021) Davis D, Tinker AV, Friedlander M. “Platinum resistant” ovarian cancer: what is it, who to treat and how to measure benefit? Rev Gynecol Oncol. 2014;133(3):624–31. (PMID: 10.1016/j.ygyno.2014.02.038) Ma J, Setton J, Lee NY, Riaz N, Powell SN. The therapeutic significance of mutational signatures from DNA repair deficiency in cancer. Rev Nat Commun. 2018;9(1):3292. (PMID: 10.1038/s41467-018-05228-y) Olaparib. Prescribing information. AstraZeneca Pharmaceuticals LP; 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf . Accessed 16 Feb 2021. Niraparib. Prescribing information. Tesaro, Inc. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208447lbl.pdf . Accessed 16 Feb 2021. Rucaparib. Prescribing information. Clovis Oncology, Inc. 2016. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209115s000lbl.pdf . Accessed 16 Feb 2021. Bevacizumab. Prescribing information. Genentech, Inc. 2021. https://www.gene.com/download/pdf/avastin_prescribing.pdf . Accessed 16 Feb 2021. Urban R, He H, Alfonso-Cristancho R, Hardesty M, Goff B. The cost of initial care for Medicare patients with advanced ovarian cancer. J Natl Compr Canc Netw. 2016;14(4):429–37. (PMID: 10.6004/jnccn.2016.0049) Suidan R, He W, Sun C, et al. Total and out-of-pocket costs of different primary management strategies in ovarian cancer. Am J Obstet Gynecol. 2019;221(2):136.e1-136.e9. (PMID: 10.1016/j.ajog.2019.04.005) Liang MI, Pisu M, Summerlin SS, et al. Extensive financial hardship among gynecologic cancer patients starting a new line of therapy. Gynecol Oncol. 2020;156(2):271–7. (PMID: 10.1016/j.ygyno.2019.11.022) Health Economics and Outcomes Research (HEOR). OPTUM. https://www.optum.com/business/solutions/life-sciences/answer-research/heor.html . Accessed 3 Feb 2021. Clinical Classification Software (CCS) for ICD-9-CM. Agency for Healthcare Research and Quality. March 2017. www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp . Accessed 17 Dec 2021. Clinical Classification Software (CCS) for ICD-10-PCS (beta version). Agency for Healthcare Research and Quality. November 2019. www.hcup-us.ahrq.gov/toolssoftware/ccs10/ccs10.jsp . Accessed 15 Feb 2021. US Department of Labor, Bureau of Labor Statistics. Chained CPI for all urban consumers, US city average (C-CPI-U). Medical Care. Series ID: SUUR0000SAM. 2012. http://data.bls.gov/cgi-bin/surveymost?su . Accessed 16 Feb 2021. Yue X, Pruemer JM, Hincapie AL, Almalki ZS, Guo JJ. Economic burden and treatment patterns of gynecologic cancers in the United States: evidence from the Medical Expenditure Panel Survey 2007–2014. J Gynecol Oncol. 2020;31(4):e52. https://doi.org/10.3802/jgo.2020.31.e52 . (PMID: 10.3802/jgo.2020.31.e52322668017286759) Ramsey S, Blough D, Kirchhoff A, et al. Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (Millwood). 2013;32(6):1143–52. (PMID: 10.1377/hlthaff.2012.1263) Ramsey SD, Bansal A, Fedorenko CR, et al. Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol. 2016;34(9):980–6. (PMID: 10.1200/JCO.2015.64.6620) Hanker LC, Loibl S, Burchardi N, AGO and GINECO study group, et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol. 2012;23(10):2605–12. https://doi.org/10.1093/annonc/mds203 . (PMID: 10.1093/annonc/mds20322910840) CancerMPact®. Cerner Enviza. https://www.cernerenviza.com/syndicated-insights-and-reports-for-life-sciences/cancermpact . Accessed 3 Mar 2022. |
| فهرسة مساهمة: | Keywords: Financial burden; Financial toxicity; Gynecologic cancers; Health care cost; Health care resource utilization; Ovarian cancer Local Abstract: [plain-language-summary] Ovarian cancer is a complex disease in which > 70% of patients are diagnosed with advanced disease, and one of the leading causes of cancer mortality among women in the United States. A variety of maintenance therapy options, including bevacizumab, PARP inhibitors, and PARP plus bevacizumab combination therapies, have demonstrated improvements in progression-free survival. By delaying disease progression after completion of first-line therapy, a simultaneous decrease in post-progression health care costs may be seen. The objective of this study was to capture the health care resource utilization and costs of patients with advanced ovarian cancer who did not receive a PARP inhibitor at any time in their treatmentIn patients never receiving a PARP inhibitor, this study documented substantial health care resource usage and costs associated with progression beyond the first line of treatment (surgery and/or chemotherapy) in ovarian cancer. These were largely driven by the number of ambulatory care visits. When these visits are combined with emergency department visits and inpatient stays, high costs are incurred by both patients and third-party payersProlonging progression-free survival after first-line treatment in patients with ovarian cancer may delay or prevent the need for later treatment, the financial burden felt by patients, and the economic burden to the health care system associated with subsequent disease progressions. |
| تواريخ الأحداث: | Date Created: 20220401 Date Completed: 20220524 Latest Revision: 20220723 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC9122852 |
| DOI: | 10.1007/s12325-022-02086-5 |
| PMID: | 35362863 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1865-8652 |
|---|---|
| DOI: | 10.1007/s12325-022-02086-5 |